Comparative Study between Intravenous Ferric Carboxymaltose versus Iron Sucrose in the Treatment of Iron Deficiency Anemia in Postpartum Patients.

Iron deficiency is the commonest cause of anemia of postpartum stage which can easily be treated. Antenatal iron therapy results rapid and increased iron storage and ensures better maintenance of Hb concentration with optimum compliance. Objective of the study was to compare whether ferric carboxymaltose are more beneficial than iron sucrose in the treatment of postpartum anemic patients. This randomized clinical trial study was carried out in the Department of Obstetrics and Gynecology of Sir Salimullah Medical College & Mitford Hospital, Dhaka, Bangladesh. A total of 70 postpartum mild to moderately anemic women during July 2021 to June 2022 were enrolled and randomly divided into two groups; Group I: receive ferric carboxymaltose and Group II: receive iron sucrose. Statistical analyze was performed by window based software with Statistical Packages for Social Sciences (SPSS-22.0). Out of 70 women 40(57.1%) had mild anemia and 30(42.9%) had moderate anemia. In mild anemia group, the mean improvement of haemoglobin was 2.51±0.01 mg/dl in Group I and 2.21±0.02 mg/dl in Group II after 4 weeks. Similarly, in moderate anemia group the mean improvement of haemoglobin was 5.15±0.01 mg/dl in Group I and 4.41±0.2 mg/dl in Group II after 4 weeks. Haemoglobin level in ferric carboxymaltose group was significantly (p<0.05) more rises with compared to iron sucrose group. Injection site problem was found 3(8.6%) in Group I and 9(25.7%) in Group II. The injection site problem was statistically significant (p>0.05) between two groups. Regarding the costing, 700Tk. had Ferric carboxymaltose in mild and 1550Tk in moderate, 1300Tk had Iron sucrose in mild and 3000Tk. in moderate. Ferric carboxymaltose is an equally effective, safe and better alternative to iron sucrose for the treatment of iron deficiency anemia in postpartum patients.